| Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma M Callea, L Albiges, M Gupta, SC Cheng, EM Genega, AP Fay, J Song, ... Cancer immunology research 3 (10), 1158-1164, 2015 | 279 | 2015 |
| The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma DF McDermott, SC Cheng, S Signoretti, KA Margolin, JI Clark, JA Sosman, ... Clinical Cancer Research 21 (3), 561-568, 2015 | 167 | 2015 |
| A Drosophila CREB/ATF transcriptional activator binds to both fat body-and liver-specific regulatory elements. T Abel, R Bhatt, T Maniatis Genes & development 6 (3), 466-480, 1992 | 166 | 1992 |
| A mouse serine/threonine kinase homologous to C. elegans UNC51 functions in parallel fiber formation of cerebellar granule neurons T Tomoda, RS Bhatt, H Kuroyanagi, T Shirasawa, ME Hatten Neuron 24 (4), 833-846, 1999 | 145 | 1999 |
| Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma RR McKay, GE Rodriguez, X Lin, MD Kaymakcalan, OPR Hamnvik, ... Clinical Cancer Research 21 (11), 2471-2479, 2015 | 134 | 2015 |
| Discoidin domain receptor 1 functions in axon extension of cerebellar granule neurons RS Bhatt, T Tomoda, Y Fang, ME Hatten Genes & Development 14 (17), 2216-2228, 2000 | 93 | 2000 |
| Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression L Zhang, M Bhasin, R Schor-Bardach, X Wang, MP Collins, D Panka, ... PLoS One 6 (4), e19144, 2011 | 84 | 2011 |
| A phase 2 pilot trial of lowdose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma RS Bhatt, J Merchan, R Parker, HK Wu, L Zhang, V Seery, JV Heymach, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 81 | 2010 |
| Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer L Zhang, X Wang, AJ Bullock, M Callea, H Shah, J Song, K Moreno, ... Clinical cancer research 21 (8), 1925-1934, 2015 | 78 | 2015 |
| KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1 RS Bhatt, A Berjis, JC Konge, KM Mahoney, AN Klee, SS Freeman, ... Cancer immunology research 9 (2), 156-169, 2021 | 69 | 2021 |
| Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling RS Bhatt, X Wang, L Zhang, MP Collins, S Signoretti, DC Alsop, ... Molecular cancer therapeutics 9 (10), 2793-2802, 2010 | 68 | 2010 |
| Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with highrisk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial RW Ross, MD Galsky, P Febbo, M Barry, JP Richie, W Xie, FM Fennessy, ... Cancer 118 (19), 4777-4784, 2012 | 65 | 2012 |
| Angiopoietin 2 is a potential mediator of high-dose interleukin 2–induced vascular leak DC Gallagher, RS Bhatt, SM Parikh, P Patel, V Seery, DF McDermott, ... Clinical cancer research 13 (7), 2115-2120, 2007 | 64 | 2007 |
| Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma DC Cho, I Puzanov, MM Regan, T Schwarzberg, V Seery, MY Lee, V Liu, ... Journal of immunotherapy 32 (2), 181-185, 2009 | 61 | 2009 |
| KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case–control study G Scelo, DC Muller, E Riboli, M Johansson, AJ Cross, P Vineis, ... Clinical Cancer Research 24 (22), 5594-5601, 2018 | 56 | 2018 |
| Statins and survival outcomes in patients with metastatic renal cell carcinoma RR McKay, X Lin, L Albiges, AP Fay, MD Kaymakcalan, SS Mickey, ... European Journal of Cancer 52, 155-162, 2016 | 53 | 2016 |
| Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma K Lasseter, AH Nassar, L Hamieh, JE Berchuck, PV Nuzzo, K Korthauer, ... Genetics in Medicine 22 (8), 1366-1373, 2020 | 52 | 2020 |
| Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts X Wang, L Zhang, A O'neill, B Bahamon, DC Alsop, JW Mier, SN Goldberg, ... British journal of cancer 108 (2), 319-326, 2013 | 49 | 2013 |
| Taxane resistance in prostate cancer is mediated by decreased drug-target engagement A Gjyrezi, F Xie, O Voznesensky, P Khanna, C Calagua, Y Bai, J Kung, ... The Journal of clinical investigation 130 (6), 3287-3298, 2020 | 48 | 2020 |
| A phase 2 study of the sphingosine1phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma SK Pal, HA Drabkin, JA Reeves, JD Hainsworth, SE Hazel, DA Paggiarino, ... Cancer 123 (4), 576-582, 2017 | 48 | 2017 |
